Viibryd- New Antidepressant approved by FDA recently

**Admin** Wed Jul 27, 2011 5:39 pm

FDA approves Viibryd to treat major depressive disorder

The U.S. Food and Drug Administration approved Viibryd tablets (vilazodone hydrochloride) to treat major depressive disorder in adults (Jan. 21, 2011).

The most frequent adverse reactions reported by patients taking Viibryd in clinical trials included diarrhea, nausea, vomiting, and insomnia.

The drug will be available in 10, 20 and 40 milligram tablets.

Viibryd and all other antidepressant drugs have a boxed warning and a patient medication guide describing the increased risk of suicidal thinking and behavior in children, adolescents, and young adults ages 18 to 24 during initial treatment. The warning also says data did not show this increased risk in adults older than 24 and that patients ages 65 and older who take antidepressants have a decreased risk of suicidal thinking and behavior. The warning says depression and other serious psychiatric disorders themselves are the most important causes of suicide and that close monitoring of patients starting these medications is necessary.

For more details: FDA (Food and Drug Administration)

Please share your experience of Viibryd use (dose, indication, side effect, etc).
Thanks

Viibryd- New Antidepressant approved by FDA recently Viibry10

Viibryd- New Antidepressant approved by FDA recently Viibry10

Mon	Tue	Wed	Thu	Fri	Sat	Sun
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30